28924-18-7

Basic information

• Product Name: 1-[3,5-bis(phenylmethoxy)phenyl]-2-bromoethan-1-one
• Synonyms: 1-[3,5-bis(phenylmethoxy)phenyl]-2-bromoethan-1-one;1-[3,5-Bis(phenylmethoxy)phenyl]-2-bromoethanone;3',5'-Bis(benzyloxy)-2-broMo-acetophenone;2-bromo-1-[3,5-bis(phenylmethoxy)phenyl]ethanone
• CAS NO: 28924-18-7
• Molecular Formula: C₂₂H₁₉BrO₃
• Molecular Weight: 411.28846
• EINECS: 249-314-1
• Product Categories: Aromatics
• Mol File: 28924-18-7.mol
• Article Data: 13

Chemical Properties

• Melting Point: 84-86°C
• Boiling Point: 523.8°Cat760mmHg
• Flash Point: 270.6°C
• Appearance: /
• Density: 1.354g/cm³
• Vapor Pressure: 4.56E-11mmHg at 25°C
• Refractive Index: 1.617
• CAS DataBase Reference: 1-[3,5-bis(phenylmethoxy)phenyl]-2-bromoethan-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[3,5-bis(phenylmethoxy)phenyl]-2-bromoethan-1-one(28924-18-7)
• EPA Substance Registry System: 1-[3,5-bis(phenylmethoxy)phenyl]-2-bromoethan-1-one(28924-18-7)

Safety Data

• Hazardous Substances Data: 28924-18-7(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

InChI:InChI=1/C22H19BrO3/c23-14-22(24)19-11-20(25-15-17-7-3-1-4-8-17)13-21(12-19)26-16-18-9-5-2-6-10-18/h1-13H,14-16H2

Upstream product

• 100-44-7 benzyl chloride 
• 51863-60-6 3,5-dihydroxyacetophenone 
• 100-39-0 benzyl bromide 
• 28917-44-4 3,5-dibenzyloxylbenzoyl chloride 
• 28917-43-3 3,5-dibenzyloxybenzoic acid 
• 58605-10-0 methyl 3,5-bis(benzyloxy)benzoate 
• 2150-44-9 1-carbomethoxy-3,5-dihydroxybenzene 
• 52144-91-9 3,5-bis(benzyloxy)diazoacetophenone 
• 28924-21-2 3,5-dibenzyloxyacetophenone 

Downstream Products

• 103145-39-7 2-bromo-1-(3,5-bis(benzyloxy)phenyl)ethanol 
• 28924-21-2 3,5-dibenzyloxyacetophenone 
• 103145-34-2 (R)-3’,5’-dibenzyloxyphenylbromohydrin 
• 37394-31-3 (-)-Terbutaline 
• 53144-56-2 (R)‐5‐(2‐(tert‐butylamino)‐1‐hydroxyethyl)benzene‐1,3‐diol hydrochloride 
• 50841-49-1 3,5-dibenzyloxyphenylglyoxal 
• 1351013-79-0 1-(3,5-bis(benzyloxy)phenyl)-2-(3,4,5-trimethoxyphenoxy)ethanone 
• 1351013-93-8 3-(3,5-bis(benzyloxy)phenyl)-4,6-dimethoxybenzofuran 
• 1351013-66-5 1-(3,5-bis(benzyloxy)phenyl)-2-(3,5-dimethoxyphenoxy)ethanone 
• 52144-90-8 3,5-dibenzyloxy-ω-(t-butylamino)acetophenone 
• 865799-38-8 methyl {3-[2-({2-[3,5-bis(benzyloxy)phenyl]-2-hydroxyethyl}amino)-2-methylpropyl]phenyl}acetate 

Relevant articles and documents

Preparation method of terbutaline sulfate (by machine translation)

The method adopts,hydroxyacetophenone as the starting material 3,5 - to obtain, di 3,5 -benzyloxyacetophenone, 3,5 - dibenzyloxyacetophenone and then generates, DMSO-benzyloxy 3,5 -phenyl,tert-butylamino 1 - [3,5 - ethanol (by hydrogenation debenzil) and sulfuric acid into a salt to obtain dibenzyloxybenzenethanone aldehyde] - 2 - (and then reductive amination with tertiary butylamine.) reaction conditions under, reaction conditions, are avoided, The method disclosed by the invention is cheap and easy to obtain and avoids the use of high-risk highly-toxic agents, by reductive amination . The method disclosed by the invention is low, reaction conditions . The method disclosed by the invention is cheap and easily available. (by machine translation)

Preparation method of high-purity injection-grade terbutaline sulfate

The invention provides a preparation method of high-purity injection-grade terbutaline sulfate. The preparation method is characterized in that 3,5-dibenzyloxyacetophenone is adopted as a raw material, a bromination reaction, a substitution reaction, carbonyl reduction and hydrogenation reduction are conducted, salifying with sulfuric acid is conducted, and the terbutaline sulfate is obtained. A synthetic route is shown in the description.

Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas

This disclosure concerns the discovery of the use of fenoterol and (R,R)- and (R,S)-fenoterol analogs for the treatment of a tumor expressing a β2-adrenergic receptor, such as a primary brain tumor, including a glioblastoma or astrocytoma expressing a β2-adrenergic receptor. In one example, the method includes administering to a subject a therapeutically effective amount of fenoterol, a specific fenoterol analog or a combination thereof to reduce one or more symptoms associated with the tumor, thereby treating the tumor in the subject.